100% online
FDA regulated pharmacies
Free expedited delivery
No hidden fees
Unlimited 24/7 support100,000+ membersKey Takeaways
- Staged public primary-care rollouts restrict Mounjaro in 2026–2027 to adults with BMI ≥35–40 (adjusted 2.5 points lower in higher-risk ethnic groups) plus 3 to 4 obesity comorbidities.
- Specialist hospital weight-management clinics require BMI ≥35 plus at least 1 comorbidity, often carrying multi-year referral waitlists.
- Regulated private telehealth prescribes Mounjaro across its full licensed clinical indication: BMI ≥30, or BMI ≥27 with at least one weight-related condition.
Because an estimated 3.4 million+ adults meet clinical obesity criteria in the United States alone — and treating every eligible patient simultaneously would strain public and private insurance budgets by billions (8) — broad primary-care access to Mounjaro (tirzepatide) is being phased in over 3 to 12 years (1,4,5).
Staged public primary-care criteria vs. licensed telehealth criteria
| Pathway & Stage | Minimum BMI Threshold* | Required Weight-Related Comorbidities** |
|---|---|---|
| Public Primary Care (to June 2026) | BMI ≥40 | 4 or more listed conditions (1) |
| Public Primary Care (from June 2026) | BMI ≥35 | 4 or more listed conditions (1) |
| Public Primary Care (from March 2027) | BMI ≥40 | 3 or more listed conditions (1) |
| Public Specialist Clinic (Referral) | BMI ≥35 | At least 1 listed condition (often 1–2 yr wait) (2) |
| Regulated Telehealth (Licensed Label) | BMI ≥30 (or BMI ≥27 w/ condition) | None at BMI ≥30; 1 condition at BMI ≥27 |
*Lowered by 2.5 kg/m² for South Asian, Chinese, Middle Eastern, Black African, and African-Caribbean backgrounds. **Listed conditions: type 2 diabetes, hypertension, cardiovascular disease, dyslipidemia, obstructive sleep apnea.
If you qualify under the medical label (BMI ≥30 or ≥27 with a comorbidity) and prefer not to wait years on regional clinic queues (6), start a confidential online consultation to review GLP-1 treatment with a licensed clinician today.
References
- U.S. Food and Drug Administration. Mounjaro (tirzepatide) prescribing information — Indications & dosing. 2024.
- KFF. How much does Medicare spend on GLP-1 drugs?. 2025.
- JAMA. Metabolic outcomes with tirzepatide across the SURMOUNT trial program. 2025.
Related Clinical Guides
Your personalizedweight care plan
Clinician-prescribed GLP-1 & metabolic care, 100% online.
Leave a Reply